Ocugen (OCGN) vs X4 Pharmaceuticals (XFOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
X4 Pharmaceuticals (XFOR) has outperformed Ocugen (OCGN) over the past year, losing 16.0% versus a loss of 45.4%. Over five years, OCGN leads with a -88.7% price change compared with -98.2% for XFOR. Ocugen is the larger company by market cap ($324.0 million vs $288.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OCGN | XFOR |
|---|---|---|
| Share price | $0.9555 | $2.91 |
| Market cap | $324.02M | $288.52M |
| 1-day change | -2.24% | +4.30% |
| YTD return | -27.60% | -30.25% |
| 1-year return | -45.40% | -15.96% |
| 5-year return | -88.71% | -98.22% |
| P/E ratio (TTM) | — | 145.50 |
| EPS (TTM) | $-0.26 | $0.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.73 | $4.83 |
| 52-week low | $0.9001 | $2.70 |
| Distance from 52-week high | -64.94% | -39.75% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +1173.68% | +298.63% |
| Average volume | 5.91M | 849.58K |
| Shares outstanding | 339.11M | 99.15M |
| Employees | 116 | 45 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XFOR has outperformed OCGN by 29.4 percentage points over the past year.
About Ocugen
OCGN stock →Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 116 employees
About X4 Pharmaceuticals
XFOR stock →X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 45 employees
OCGN vs XFOR FAQ
Which is bigger, Ocugen or X4 Pharmaceuticals?
Ocugen (OCGN) is larger, with a market capitalization of $324.02M compared with $288.52M for X4 Pharmaceuticals (XFOR).
Which stock has performed better over the past year, OCGN or XFOR?
XFOR returned -15.96% over the past 12 months, compared with -45.40% for OCGN (price return, excluding dividends). Past performance does not predict future results.
Are Ocugen and X4 Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.